Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis
Authors:
- Philipp LatzinPLPhilipp Latzin
- Maya FehlingMFMaya Fehling
- Adolf BauernfeindABAdolf Bauernfeind
- Dietrich ReinhardtDRDietrich Reinhardt
- Matthias KapplerMKMatthias Kappler
- Matthias GrieseMGMatthias Griese
- 1 March 2008
- journal article
- research article
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 7 (2) , 142-146
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- The Efficacy and Safety of Meropenem and Tobramycin vs Ceftazidime and Tobramycin in the Treatment of Acute Pulmonary Exacerbations in Patients With Cystic FibrosisChest, 2005
- Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis?the TOPIC study: a randomised controlled trialThe Lancet, 2005
- Pathophysiology and Management of Pulmonary Infections in Cystic FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Lack of concordance in the use and monitoring of intravenous aminoglycosides in UK cystic fibrosis centersPediatric Pulmonology, 2002
- Changes in strategies for optimal antibacterial therapy in cystic fibrosisInternational Journal of Antimicrobial Agents, 2001
- The Treatment of Respiratory Pseudomonas Infection in Cystic FibrosisDrugs, 2000
- Management of Pulmonary Disease in Patients with Cystic FibrosisNew England Journal of Medicine, 1996
- Qualitative and quantitative microbiological analysis of sputa of 102 patients with cystic fibrosisInfection, 1987
- Clinical and Bacteriological Responses to Three Antibiotic Regimens for Acute Exacerbations of Cystic Fibrosis: Tlcarcillln-Tobramycin, Azlocillin-Tobramycin, and Azlocillin-PlaceboThe Journal of Infectious Diseases, 1983
- A double-blind controlled trial of anti-Pseudomonas chemotherapy of acute respiratory exacerbations in patients with cystic fibrosisThe Journal of Pediatrics, 1981